Abstract. Recent reports have demonstrated that another strand of mature microRNA (miRNA), called microRNA * or 3p (5p) strand, which is generated from the same precursor miRNA (Pre-miR), has a crucial role in cellular function. We previously reported the tumor suppressive effect of miR-125a-5p in gastric cancer. The current study was designed to examine the function and clinical significance of miR-125a-3p, a partner strand of miR-125a-5p, in human gastric cancer. Quantitative RT-PCR was used to evaluate miR-125a-3p expression in 70 gastric cancer cases to determine the clinicopathologic significance of miR-125a-3p expression. In addition, the effect of miR-125a-3p on the proliferation of gastric cancer cells was investigated. Low expression levels of miR-125a-3p were associated with indicators of enhanced malignant potential such as tumor size (p=0.0002), tumor invasion (p=0.0149), lymph node metastasis (p=0.018), liver metastasis (p=0.016), peritoneal dissemination (p=0.03), advanced clinical stage (p=0.0037) and poor prognosis (p=0.0083). Multivariate analysis indicated that low miR-125a-3p expression was an independent prognostic factor for survival, while in vitro assays demonstrated that miR-125a-3p suppressed the proliferation of gastric cancer cells. MiR-125a-3p is a potent prognostic marker in gastric cancer. The clinical significance and tumor suppressive effect of miR-125a-3p, as well as previously reported miR-125a-5p, suggest that the functional role of another strand of the mature form miRNA cannot be ignored, at least in miR-125a biogenesis.
Introduction
Gastric cancer is one of the most common cancers in Asian countries, including China, Korea and Japan. In Japan, over fifty thousand new cases are diagnosed each year. It is the leading cause of malignancies in males, the second leading cause in females, and the second largest cause of cancer mortality in both male and female (1,2). 5-fluorouracil (5-FU)-based adjuvant or neoadjuvant chemotherapy improved the 5-year overall survival rate to more than 50% in stage I-III patients. However, advanced cases with peritoneal dissemination or distant metastasis cannot be controlled, and the 5-year overall survival rate of stage IV patients is under 10% (3) . In these advanced cases, molecular targeted therapy including trastuzumab, a monoclonal antibody against the ERBB2 gene, is now in clinical use, and molecular targeted therapy is considered as a promising new strategy against gastric cancer (4) .
Alternations in miRNA expression have been implicated in the initiation, progression, and metastasis of a number of human cancers (5) . miRNAs constitute a class of small (19-25 nucleotides), non-coding RNAs that function as post-transcriptional gene regulators (6) (7) (8) . In gastric cancer, oncogenic miRNAs such as the miR-93-106b cluster and miR-21, are associated with cancer progression (9) (10) (11) (12) (13) (14) , and targeted therapy against these miRNAs is under development. Previously, we demonstrated the tumor suppressive effect of miR-125a-5p in human gastric cancer (10) .
In the current study, we focused on miR-125a-3p, which is generated as another strand of miR-125a-5p in the maturation process from precursor double strand RNA (pre-miRNA). Another strand of mature form miRNA, called microRNA * strand species or 3p (5p) strand, has been regarded as a passenger strand and not been extensively investigated. However, recent reports indicate that a substantial fraction of microRNA * strand species is broadly conserved among vertebrates, and that it might have cellular functions (15, 16 
Materials and methods

Clinical cases
Patients and sample collection. Seventy gastric cancer and paired normal gastric tissue samples were obtained during surgery and used after obtaining informed consent. All patients underwent resection of the primary tumor at Kyushu University Hospital at Beppu and affiliated hospitals between 1992 and 2000. All patients had a clear histological diagnosis of gastric cancer, based on the clinicopathologic criteria described by the Japanese Gastric Cancer Association (17), and were closely followed every 3 months. The follow-up periods ranged from 0.2 months to 12.3 years, with a mean of 2.6 years. Resected cancer tissues were immediately cut and embedded in TissueTek OCT medium (Sakura), frozen in liquid nitrogen, and kept at -80˚C until RNA and DNA extraction. Frozen tissue specimens were homogenized in guanidium thiocyanate, and total RNA was obtained by ultracentrifugation through a cesium chloride cushion. cDNA was synthesized from 8.0 µg of total RNA as previously described (18) . Clinicopathological factors and clinical stages were classified by the criteria of the Japanese Gastric Cancer Association (17) . All sample data, including age, gender, tumor size and depth, lymphatic invasion, lymph node metastasis, vascular invasion, liver metastasis, peritoneal dissemination, distant metastasis, clinical stage and histological grade were obtained from the clinical and pathologic records, and are summarized in Table I . Written informed consent for study participation was obtained from all patients.
Evaluation of miR-125a-3p and miR-125a-5p expression in clinical samples. For miR-125a-3p and miR-125a-5p quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR), cDNA was synthesized from 10 ng of total RNA using TaqMan™ MicroRNA hsa-miR-125a-3p and hsa-miR125a-5p specific primers (Applied Biosystems) and a TaqMan™ MicroRNA Reverse Transcription Kit (Applied Biosystems). The following temperature profile was used: initial denaturation at 95˚C for 10 min, followed by 45 cycles of denaturation at 95˚C for 10 sec, annealing at 60˚C for 10 sec, and extension at 65˚C for 10 sec. PCR was performed in a LightCycler™ 480 System (Roche Applied Science) using the LightCycler™ 480 Probes Master Kit (Roche Applied Science). Expression levels of miR-125a-3p were normalized to that of the small nuclear RNA RNU6B (Applied Biosystems) transcript. Each assay was performed three times to verify the results, and the mean normalized value of mRNA expression was used for subsequent analyses.
Experimental studies
Cell lines and cell culture. The human gastric cancer cell lines MKN7 and NUGC4 were provided by the Cell Resource Center of Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University. These cell lines were cultured in a humidified 5% CO 2 incubator at 37˚C using RPMI-1640 supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 units/ml streptomycin sulfates.
Transfection of microRNA-125a-3p precursor (Pre-miR™-125a-3p).
Using NUGC4, a gastric cancer cell line that expresses a high level of ERBB2 mRNA, either Pre-miR-125a-3p or Pre-miR negative control (Ambion ® Pre-miR™ miRNA Precursors Applied Biosystems Japan Ltd.) was transfected at 30 nM (final concentration) using Lipofectamine™ RNAiMAX (Invitrogen Life Technologies) according to the manufacturer's instructions. Pre-miR-125a-3p, the double-stranded precursor Table I . miR-125a-3p expression and clinicopathological factors. microRNA product, produced only a functional 3p strand when introduced into cells.
In vitro assays The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for gastric cancer cell growth after transfection with Pre-miR-125a.
Logarithmically growing NUGC4 and MKN7 cells were transfected with Pre-miR-125a-3p or Pre-miR negative control and were seeded at 8.0x10 3 cells/well in 96-well flat-bottomed microtiter plates, in a final volume of 100 µl of culture medium per well. Cells were incubated in a humidified atmosphere (37˚C and 5% CO 2 ) for 24, 48, or 72 h after the initiation of transfection. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Roche Diagnostics Corp.) was used to measure cell growth inhibition. After incubation, 10 µl of MTT labeling reagent (final concentration of 0.5 mg/ml) was added to each well, and the plate was incubated for 4 h in a humidified atmosphere. Solubilization solution (100 µl) was added to each well, and the plate was incubated overnight in a humidified atmosphere. After confirming that the purple formazan crystals were completely solubilized, the absorbance of each well was measured by a Model 550 series microplate reader (Bio-Rad Laboratories), at a wavelength of 570 nm corrected to 655 nm. The assay was performed using six replicates.
Statistical analysis. Data from RT-PCR analysis and in vitro
transfection cell assays were analyzed with JMP 5. Overall survival rates were calculated actuarially according to the Kaplan-Meier method and were measured from the day of surgery. Differences between groups were estimated using the χ 2 test, Student's t-test, repeated-measures ANOVA test, and the log-rank test. Variables with a value of p<0.05 in univariate analysis were used in a subsequent multivariate analysis based on the Cox proportional hazards model. A probability level of 0.05 was chosen for statistical significance.
Results
The clinicopathologic significance of miR-125a-3p expression in gastric cancer. The expression level of miR-125a-3p
is significantly higher in normal tissue compared with paired cancerous tissue (Fig. 1) . The 70 colon cancer cases were classified into two groups according to the median ratio of miR-125a-3p expression level (7.419, normalized to RNU6B) as determined by quantitative RT-PCR. Thirty-five cases were placed in the high expression group and 35 in the low expression group. The association between clinicopathological features and miR-125a-3p expression is summarized in Table I. In the low expression group, malignant potential such as tumor size, tumor invasion, lymph node metastasis, liver metastases, peritoneal dissemination, and clinical classification were enhanced compared to the high miR-125a-3p expression group (p<0.05). However, no significant differences were observed regarding age, gender, and histology. Univariate analysis identified miR-125a-3p expression, tumor invasion, lymph node metastasis, lymphatic invasion and venous invasion as prognostic factors for 5-year overall survival after surgery. Variables with a p-value <0.05 by univariate analysis were selected for multivariate analysis using Cox's proportional hazards model. miR-125a-3p expression [relative risk (RR): 1.796, confidence interval (CI): 1.16-2.87, p= 0.0083] was found to be a significant factor affecting 5-year overall survival after surgery (Table II) . Analysis of the 5-year overall survival curves showed that patients in the low miR-125a-3p expression group had a significantly poorer prognosis than those in the high expression group (p<0.05) (Fig. 2) .
miR-125a-5p expression is significantly associated with miR-125a-3p expression.
To investigate both strands of mature miRNAs derived from precursor miR-125a, miR-125a-5p expression was also assayed in the same samples in which miR-125a-3p expression had been measured by RT-PCR Figure 2 . Kaplan-Meier overall survival curves of gastric cancer patients according to the level of miR-125a-3p expression. The high miR-125a-3p expression group (n=35) was composed of patients with a higher than median ratio of expression (7.419, normalized to RNU6B); the low miR-125a-5p expression group (n=35) exhibited a lower than median ratio. analysis. The expression levels of the two mature of miRNAs were significantly correlated (Fig. 3, r 2 =0.5918, p<0.0001).
miR-125a-3p inhibited the proliferation of gastric cancer cells. A proliferation assay was performed with parent cells,
Pre-miR-125a-3p treated cells and negative control cells using two gastric cancer cell lines, MKN7 and NUGC4. The expression of miR-125a-3p in Pre-miR-125a-3p transfected cells was significantly higher than in parental and negative control pre-miR transfected cells (Fig. 4A, p<0 .05). The assay confirmed that miR-125a-3p significantly suppresses the proliferative activity of gastric cancer cells in both cell lines (Fig. 4B ).
Discussion
In this study, we show that miR-125a-3p expression is significantly associated with cancer progression and prognosis in human gastric cancer. miR-125a-3p is significantly down-regulated in gastric cancer tissues compared with corresponding normal tissues (Fig. 1 ). This finding suggests that miR-125a-3p is involved in gastric carcinogenesis. Clinicopathological analysis revealed that low miR-125a-3p expression contributes to more advanced tumor size, tumor invasion, lymph node metastasis, liver metastases, peritoneal dissemination, and poor prognosis (Table I , Fig. 2 ). Multivariate analysis revealed that miR-125a-3p is an independent prognostic factor for survival (Table II) . These data suggest a tumor suppressive role for miR-125a-3p in gastric cancer. The expression of miR-125a-3p is reportedly down-regulated in non-small cell lung cancer (19) . In contrast, it is up-regulated in synovial sarcoma (20) , and overexpression under hypoxic conditions in retinoblastoma has also been observed (21) . miR-125a-5p, the partner of miR-125a-3p, is down-regulated in breast cancer (22) (23) (24) , ovarian cancer (25) , lung cancer (26) , and medulloblastoma (27) , indicating its tumor suppressive effect in human cancers. However, only a few reports have demonstrated a functional role for miR-125a-3p, and this is the first describing the clinical significance of miR-125a-3p in gastrointestinal cancer.
In vitro studies revealed that miR-125a-3p suppresses the proliferation of gastric cancer cells. We previously demonstrated the same inhibitory effect of miR-125a-5p on cell proliferation. Therefore, these two mature miRNAs act similarly. Because these two strands are generated simultaneously from the same precursor, the expression levels of miR-125a-3p and 5p are significantly associated with each other (Fig. 3) . RT-PCR showed that the two strands are equally expressed when normalized to an internal control, suggesting that both strands contribute to cellular function to the same extent. Jiang and colleagues previously demonstrated that miR-125a-3p and miR-125a-5p exert inverse effects on the invasion and migration of lung cancer cells (19) , which is possible because each strand regulates a number of different target genes. Nevertheless, at least regarding the proliferation of gastric cancer cells, our data revealed that miR-125a-3p and miR-125a-5p work similarly to inhibit proliferation. The tumor suppressive effect of miR-125a-3p as well as miR-125a-5p leads to the conclusion that the functional role of another strand of mature form miRNA cannot be ignored, at least in miR-125a biogenesis. Regarding miRNA therapy, some preclinical data suggest that a delivery system using adenovirus-associated vector (AAV) is reasonable for a strategy of tumor suppressive miRNA replacement (28) . In this delivery system, restoring downregulated miRNA expression could be achieved by inserting genes coding for miRNAs into viral constructs (28, 29) . Thus, the virus would ensure that both strands of individual miRNAs are equally transcribed. miRNAs for which the function of both mature forms are clearly defined, such as miR-125a, could be useful in obtaining an anti-proliferation effect of miRNA.
In conclusion, we demonstrated that miR-125a-3p is a meaningful prognostic marker in gastric cancer. Furthermore, miR-125a mimic could be a novel therapeutic approach against gastric cancer.
